Key Takeaways
- • Astorg plans for portfolio company Oxoid Remel to acquire the microbiology diagnostics division of Solabia, which includes Biokar Diagnostics.
- • Astorg acquired Oxoid Remel from Thermo Fisher Scientific in August 2026, and Oxoid Remel CEO Dirk Bontridder is set to run the combined business.
- • Solabia is narrowing its focus to cosmetics, nutrition and life sciences by divesting its microbiology diagnostics unit.
- • The division focuses on microbiological culture media, particularly for food and beverage testing.
Summary
Astorg plans to combine two of its portfolio companies, with Oxoid Remel Microbiology proposing to acquire the microbiology diagnostics division of Solabia, according to the primary source. The move would bring together Oxoid Remel's existing diagnostics business with the Solabia unit.
Astorg acquired Oxoid Remel from Thermo Fisher Scientific in August 2026. Dirk Bontridder, CEO of Oxoid Remel, is slated to lead the combined business following the transaction.
Solabia's microbiology diagnostics division, which includes Biokar Diagnostics, develops microbiological culture media, with a particular focus on food and beverage testing. The seller is narrowing its strategic focus to cosmetics, nutrition and life sciences.
The source article is partially paywalled, so specific deal terms, valuation and financial details were not available in the material reviewed.
Astorg acquired Oxoid Remel from Thermo Fisher Scientific in August 2026. Dirk Bontridder, CEO of Oxoid Remel, is slated to lead the combined business following the transaction.
Solabia's microbiology diagnostics division, which includes Biokar Diagnostics, develops microbiological culture media, with a particular focus on food and beverage testing. The seller is narrowing its strategic focus to cosmetics, nutrition and life sciences.
The source article is partially paywalled, so specific deal terms, valuation and financial details were not available in the material reviewed.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.